Staphylococcus aureus decolonization: Difference between revisions

From IDWiki
Staphylococcus aureus decolonization
No edit summary
()
 
(8 intermediate revisions by the same user not shown)
Line 1: Line 1:
  +
* [[Staphylococcus aureus]] is commonly found in the nares and on the skin of healthy people
* 4% rinse-off chlorhexidine for daily bathing or showering
 
  +
* Asymptomatic colonization is associated with a higher rate of invasive infection
* 0.12% chlorhexidine mouthwash twice daily
 
  +
* 2% nasal mupirocin twice daily
 
  +
== Project CLEAR ==
* All administered for five days twice per month for six months
 
  +
  +
* Probably has the best evidence, with an RCT[[CiteRef::huang2019de]]
 
* Decolonization happens for 5 days, twice monthly, for 6 months
 
** 4% rinse-off chlorhexidine for daily bathing or showering
 
** 0.12% chlorhexidine mouthwash twice daily
 
** 2% nasal mupirocin twice daily
  +
* NNT of about 30 to prevent one infection or one hospitalization
  +
  +
== Dutch Method ==
  +
  +
* Also has some evidence, with an observational study[[CiteRef::ammerlaan2011er]]
  +
* Separates patients into uncomplicated (essentially entirely asymptomatic carriage in a low-risk patient) and complicated
  +
* In the above report, the only reported outcome was decolonization
  +
** 63% after 1 cycle, and 80% after up to 5 cycles of treatment
  +
** 97% remained decolonized at 3 month follow-up
  +
  +
=== Uncomplicated carriage ===
  +
  +
* Topical treatment (5 days)
  +
** Mupirocin 2% to nares q8h
  +
** Chlorhexidine or povidone iodide soap applied once daily
  +
* Hygienic measures
  +
** Clean underwear, clothing, washcloths and towels daily
  +
** Change bedsheets every other day during treatment
  +
  +
=== Complicated carriage ===
  +
  +
* As above, plus oral antibiotics
  +
* [[Trimethoprim]] 200 mg PO BID or [[doxycycline]] 200 mg PO once daily, plus [[rifampin]] 600 mg twice a day for 1 week
  +
* Alternative: [[clindamycin]] 600 mg PO TID or [[clarithromycin]] 500 mg PO BID or [[ciprofloxacin]] 750 mg PO BID or [[fusidic acid]] 500 mg PO TID, plus [[fusidic acid]] 500 mg PO TID
   
 
{{DISPLAYTITLE:''Staphylococcus aureus'' decolonization}}
 
{{DISPLAYTITLE:''Staphylococcus aureus'' decolonization}}

Latest revision as of 08:52, 18 August 2021

  • Staphylococcus aureus is commonly found in the nares and on the skin of healthy people
  • Asymptomatic colonization is associated with a higher rate of invasive infection

Project CLEAR

  • Probably has the best evidence, with an RCT1
  • Decolonization happens for 5 days, twice monthly, for 6 months
    • 4% rinse-off chlorhexidine for daily bathing or showering
    • 0.12% chlorhexidine mouthwash twice daily
    • 2% nasal mupirocin twice daily
  • NNT of about 30 to prevent one infection or one hospitalization

Dutch Method

  • Also has some evidence, with an observational study2
  • Separates patients into uncomplicated (essentially entirely asymptomatic carriage in a low-risk patient) and complicated
  • In the above report, the only reported outcome was decolonization
    • 63% after 1 cycle, and 80% after up to 5 cycles of treatment
    • 97% remained decolonized at 3 month follow-up

Uncomplicated carriage

  • Topical treatment (5 days)
    • Mupirocin 2% to nares q8h
    • Chlorhexidine or povidone iodide soap applied once daily
  • Hygienic measures
    • Clean underwear, clothing, washcloths and towels daily
    • Change bedsheets every other day during treatment

Complicated carriage


References

  1. ^  Susan S. Huang, Raveena Singh, James A. McKinnell, Steven Park, Adrijana Gombosev, Samantha J. Eells, Daniel L. Gillen, Diane Kim, Syma Rashid, Raul Macias-Gil, Michael A. Bolaris, Thomas Tjoa, Chenghua Cao, Suzie S. Hong, Jennifer Lequieu, Eric Cui, Justin Chang, Jiayi He, Kaye Evans, Ellena Peterson, Gail Simpson, Philip Robinson, Chester Choi, Charles C. Bailey, James D. Leo, Alpesh Amin, Donald Goldmann, John A. Jernigan, Richard Platt, Edward Septimus, Robert A. Weinstein, Mary K. Hayden, Loren G. Miller. Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers. New England Journal of Medicine. 2019;380(7):638-650. doi:10.1056/nejmoa1716771.